JP2014506888A - アデニンヌクレオチドトランスケータ２ｍＲＮＡ発現を減少させて乳房癌を治療する方法 - Google Patents
アデニンヌクレオチドトランスケータ２ｍＲＮＡ発現を減少させて乳房癌を治療する方法 Download PDFInfo
- Publication number
- JP2014506888A JP2014506888A JP2013554383A JP2013554383A JP2014506888A JP 2014506888 A JP2014506888 A JP 2014506888A JP 2013554383 A JP2013554383 A JP 2013554383A JP 2013554383 A JP2013554383 A JP 2013554383A JP 2014506888 A JP2014506888 A JP 2014506888A
- Authority
- JP
- Japan
- Prior art keywords
- ant2
- breast cancer
- cells
- shrna
- expression
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 206010006187 Breast cancer Diseases 0.000 title claims abstract description 176
- 208000026310 Breast neoplasm Diseases 0.000 title claims abstract description 176
- 230000014509 gene expression Effects 0.000 title claims abstract description 148
- 238000000034 method Methods 0.000 title claims abstract description 58
- 108020004999 messenger RNA Proteins 0.000 title claims abstract description 33
- GFFGJBXGBJISGV-UHFFFAOYSA-N adenyl group Chemical class N1=CN=C2N=CNC2=C1N GFFGJBXGBJISGV-UHFFFAOYSA-N 0.000 title claims 5
- 210000004027 cell Anatomy 0.000 claims abstract description 371
- 102100026396 ADP/ATP translocase 2 Human genes 0.000 claims abstract description 281
- 239000004055 small Interfering RNA Substances 0.000 claims abstract description 272
- 108091027967 Small hairpin RNA Proteins 0.000 claims abstract description 235
- 210000000130 stem cell Anatomy 0.000 claims abstract description 64
- 108020004459 Small interfering RNA Proteins 0.000 claims abstract description 45
- 239000000203 mixture Substances 0.000 claims abstract description 37
- 239000002246 antineoplastic agent Substances 0.000 claims abstract description 28
- 230000001225 therapeutic effect Effects 0.000 claims abstract description 15
- 206010027476 Metastases Diseases 0.000 claims abstract description 12
- 230000009401 metastasis Effects 0.000 claims abstract description 12
- 239000004480 active ingredient Substances 0.000 claims abstract description 11
- 101000718417 Homo sapiens ADP/ATP translocase 2 Proteins 0.000 claims abstract 16
- 230000000694 effects Effects 0.000 claims description 98
- 102100024598 Tumor necrosis factor ligand superfamily member 10 Human genes 0.000 claims description 86
- 101710097160 Tumor necrosis factor ligand superfamily member 10 Proteins 0.000 claims description 85
- 206010028980 Neoplasm Diseases 0.000 claims description 73
- 201000011510 cancer Diseases 0.000 claims description 53
- 101001012157 Homo sapiens Receptor tyrosine-protein kinase erbB-2 Proteins 0.000 claims description 52
- 102100030086 Receptor tyrosine-protein kinase erbB-2 Human genes 0.000 claims description 52
- 102100022595 Broad substrate specificity ATP-binding cassette transporter ABCG2 Human genes 0.000 claims description 30
- 101710176164 Broad substrate specificity ATP-binding cassette transporter ABCG2 Proteins 0.000 claims description 30
- 230000009257 reactivity Effects 0.000 claims description 29
- AOJJSUZBOXZQNB-TZSSRYMLSA-N Doxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-TZSSRYMLSA-N 0.000 claims description 26
- 102100025064 Cellular tumor antigen p53 Human genes 0.000 claims description 25
- 101000721661 Homo sapiens Cellular tumor antigen p53 Proteins 0.000 claims description 24
- 230000007423 decrease Effects 0.000 claims description 24
- 101000610609 Homo sapiens Tumor necrosis factor receptor superfamily member 10D Proteins 0.000 claims description 23
- 102100040110 Tumor necrosis factor receptor superfamily member 10D Human genes 0.000 claims description 23
- 230000002829 reductive effect Effects 0.000 claims description 23
- 101000610602 Homo sapiens Tumor necrosis factor receptor superfamily member 10C Proteins 0.000 claims description 21
- 102100040115 Tumor necrosis factor receptor superfamily member 10C Human genes 0.000 claims description 20
- 229960004679 doxorubicin Drugs 0.000 claims description 13
- 102000005962 receptors Human genes 0.000 claims description 10
- 108020003175 receptors Proteins 0.000 claims description 10
- 230000015556 catabolic process Effects 0.000 claims description 7
- 238000006731 degradation reaction Methods 0.000 claims description 7
- 230000000692 anti-sense effect Effects 0.000 claims description 2
- 230000001965 increasing effect Effects 0.000 abstract description 31
- 206010059866 Drug resistance Diseases 0.000 abstract description 14
- 229940041181 antineoplastic drug Drugs 0.000 abstract description 13
- 230000002401 inhibitory effect Effects 0.000 abstract description 9
- 229940124597 therapeutic agent Drugs 0.000 abstract description 7
- 239000012830 cancer therapeutic Substances 0.000 abstract description 4
- 108010077324 Adenine Nucleotide Translocator 2 Proteins 0.000 description 265
- 102000002259 TNF-Related Apoptosis-Inducing Ligand Receptors Human genes 0.000 description 69
- 108090000623 proteins and genes Proteins 0.000 description 56
- 102100032912 CD44 antigen Human genes 0.000 description 45
- 101000868273 Homo sapiens CD44 antigen Proteins 0.000 description 45
- 108010000449 TNF-Related Apoptosis-Inducing Ligand Receptors Proteins 0.000 description 42
- 230000030833 cell death Effects 0.000 description 42
- 102000004169 proteins and genes Human genes 0.000 description 32
- 238000002474 experimental method Methods 0.000 description 29
- 108091007178 TNFRSF10A Proteins 0.000 description 27
- 230000003247 decreasing effect Effects 0.000 description 24
- 101710113864 Heat shock protein 90 Proteins 0.000 description 22
- 238000011282 treatment Methods 0.000 description 21
- 108050007957 Cadherin Proteins 0.000 description 19
- 108010073929 Vascular Endothelial Growth Factor A Proteins 0.000 description 19
- 102000005789 Vascular Endothelial Growth Factors Human genes 0.000 description 19
- 108010019530 Vascular Endothelial Growth Factors Proteins 0.000 description 19
- 210000000069 breast epithelial cell Anatomy 0.000 description 19
- 230000008774 maternal effect Effects 0.000 description 18
- 239000003814 drug Substances 0.000 description 14
- 239000013598 vector Substances 0.000 description 14
- 108020004414 DNA Proteins 0.000 description 13
- 108010076557 Matrix Metalloproteinase 14 Proteins 0.000 description 13
- 102100030216 Matrix metalloproteinase-14 Human genes 0.000 description 13
- 102000000905 Cadherin Human genes 0.000 description 11
- 102400000888 Cholecystokinin-8 Human genes 0.000 description 10
- 101800005151 Cholecystokinin-8 Proteins 0.000 description 10
- 230000022534 cell killing Effects 0.000 description 10
- 229940079593 drug Drugs 0.000 description 10
- 239000013642 negative control Substances 0.000 description 10
- IZTQOLKUZKXIRV-YRVFCXMDSA-N sincalide Chemical compound C([C@@H](C(=O)N[C@@H](CCSC)C(=O)NCC(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC=1C=CC=CC=1)C(N)=O)NC(=O)[C@@H](N)CC(O)=O)C1=CC=C(OS(O)(=O)=O)C=C1 IZTQOLKUZKXIRV-YRVFCXMDSA-N 0.000 description 10
- 230000004614 tumor growth Effects 0.000 description 10
- 241000701161 unidentified adenovirus Species 0.000 description 10
- 238000001262 western blot Methods 0.000 description 10
- 102000010400 1-phosphatidylinositol-3-kinase activity proteins Human genes 0.000 description 9
- 108091007960 PI3Ks Proteins 0.000 description 9
- 238000010240 RT-PCR analysis Methods 0.000 description 9
- 239000003153 chemical reaction reagent Substances 0.000 description 9
- 238000001415 gene therapy Methods 0.000 description 9
- 210000004881 tumor cell Anatomy 0.000 description 9
- 102100034343 Integrase Human genes 0.000 description 8
- 108010092799 RNA-directed DNA polymerase Proteins 0.000 description 8
- 230000008859 change Effects 0.000 description 8
- 230000005012 migration Effects 0.000 description 8
- 238000013508 migration Methods 0.000 description 8
- 102100026802 72 kDa type IV collagenase Human genes 0.000 description 7
- 101000627872 Homo sapiens 72 kDa type IV collagenase Proteins 0.000 description 7
- 101000990902 Homo sapiens Matrix metalloproteinase-9 Proteins 0.000 description 7
- 102100030412 Matrix metalloproteinase-9 Human genes 0.000 description 7
- 102000044209 Tumor Suppressor Genes Human genes 0.000 description 7
- 108700025716 Tumor Suppressor Genes Proteins 0.000 description 7
- 230000009421 cellmass formation Effects 0.000 description 7
- 238000006243 chemical reaction Methods 0.000 description 7
- 230000004069 differentiation Effects 0.000 description 7
- 230000003993 interaction Effects 0.000 description 7
- 230000009545 invasion Effects 0.000 description 7
- 230000008054 signal transmission Effects 0.000 description 7
- KIUKXJAPPMFGSW-DNGZLQJQSA-N (2S,3S,4S,5R,6R)-6-[(2S,3R,4R,5S,6R)-3-Acetamido-2-[(2S,3S,4R,5R,6R)-6-[(2R,3R,4R,5S,6R)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-DNGZLQJQSA-N 0.000 description 6
- 102000004190 Enzymes Human genes 0.000 description 6
- 108090000790 Enzymes Proteins 0.000 description 6
- 102000002274 Matrix Metalloproteinases Human genes 0.000 description 6
- 108010000684 Matrix Metalloproteinases Proteins 0.000 description 6
- 230000034994 death Effects 0.000 description 6
- 229920002674 hyaluronan Polymers 0.000 description 6
- 229960003160 hyaluronic acid Drugs 0.000 description 6
- 230000003834 intracellular effect Effects 0.000 description 6
- 238000004519 manufacturing process Methods 0.000 description 6
- 101150072670 ANT2 gene Proteins 0.000 description 5
- 102220497176 Small vasohibin-binding protein_T47D_mutation Human genes 0.000 description 5
- 101100108265 Zea mays ANT2 gene Proteins 0.000 description 5
- 230000003321 amplification Effects 0.000 description 5
- 210000000170 cell membrane Anatomy 0.000 description 5
- 201000010099 disease Diseases 0.000 description 5
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 5
- 239000013604 expression vector Substances 0.000 description 5
- 230000001939 inductive effect Effects 0.000 description 5
- 230000002147 killing effect Effects 0.000 description 5
- 239000002105 nanoparticle Substances 0.000 description 5
- 238000003199 nucleic acid amplification method Methods 0.000 description 5
- 230000008520 organization Effects 0.000 description 5
- 229940118537 p53 inhibitor Drugs 0.000 description 5
- 239000013641 positive control Substances 0.000 description 5
- 230000001105 regulatory effect Effects 0.000 description 5
- 239000000126 substance Substances 0.000 description 5
- 230000007730 Akt signaling Effects 0.000 description 4
- 102000001301 EGF receptor Human genes 0.000 description 4
- 108060006698 EGF receptor Proteins 0.000 description 4
- 108010040476 FITC-annexin A5 Proteins 0.000 description 4
- 239000005089 Luciferase Substances 0.000 description 4
- 229920002873 Polyethylenimine Polymers 0.000 description 4
- 239000000969 carrier Substances 0.000 description 4
- 238000002512 chemotherapy Methods 0.000 description 4
- 238000010367 cloning Methods 0.000 description 4
- 231100000371 dose-limiting toxicity Toxicity 0.000 description 4
- 230000006870 function Effects 0.000 description 4
- 238000000338 in vitro Methods 0.000 description 4
- 108010082117 matrigel Proteins 0.000 description 4
- 230000007246 mechanism Effects 0.000 description 4
- 230000002018 overexpression Effects 0.000 description 4
- 230000026731 phosphorylation Effects 0.000 description 4
- 238000006366 phosphorylation reaction Methods 0.000 description 4
- 230000019491 signal transduction Effects 0.000 description 4
- 238000010186 staining Methods 0.000 description 4
- AYUNIORJHRXIBJ-TXHRRWQRSA-N tanespimycin Chemical compound N1C(=O)\C(C)=C\C=C/[C@H](OC)[C@@H](OC(N)=O)\C(C)=C\[C@H](C)[C@@H](O)[C@@H](OC)C[C@H](C)CC2=C(NCC=C)C(=O)C=C1C2=O AYUNIORJHRXIBJ-TXHRRWQRSA-N 0.000 description 4
- 229950007866 tanespimycin Drugs 0.000 description 4
- 210000001519 tissue Anatomy 0.000 description 4
- 101710103970 ADP,ATP carrier protein Proteins 0.000 description 3
- 101710133192 ADP,ATP carrier protein, mitochondrial Proteins 0.000 description 3
- 238000011729 BALB/c nude mouse Methods 0.000 description 3
- 206010010144 Completed suicide Diseases 0.000 description 3
- 108060001084 Luciferase Proteins 0.000 description 3
- 108010040002 Tumor Suppressor Proteins Proteins 0.000 description 3
- 102000001742 Tumor Suppressor Proteins Human genes 0.000 description 3
- 238000002835 absorbance Methods 0.000 description 3
- 230000004913 activation Effects 0.000 description 3
- 238000004458 analytical method Methods 0.000 description 3
- 238000010171 animal model Methods 0.000 description 3
- 230000033228 biological regulation Effects 0.000 description 3
- KQNZDYYTLMIZCT-KQPMLPITSA-N brefeldin A Chemical compound O[C@@H]1\C=C\C(=O)O[C@@H](C)CCC\C=C\[C@@H]2C[C@H](O)C[C@H]21 KQNZDYYTLMIZCT-KQPMLPITSA-N 0.000 description 3
- JUMGSHROWPPKFX-UHFFFAOYSA-N brefeldin-A Natural products CC1CCCC=CC2(C)CC(O)CC2(C)C(O)C=CC(=O)O1 JUMGSHROWPPKFX-UHFFFAOYSA-N 0.000 description 3
- 230000005754 cellular signaling Effects 0.000 description 3
- 238000003776 cleavage reaction Methods 0.000 description 3
- 210000000805 cytoplasm Anatomy 0.000 description 3
- 229940127089 cytotoxic agent Drugs 0.000 description 3
- 230000001419 dependent effect Effects 0.000 description 3
- 210000002919 epithelial cell Anatomy 0.000 description 3
- 238000001727 in vivo Methods 0.000 description 3
- 238000001764 infiltration Methods 0.000 description 3
- 230000008595 infiltration Effects 0.000 description 3
- 230000033001 locomotion Effects 0.000 description 3
- 210000003470 mitochondria Anatomy 0.000 description 3
- 230000002062 proliferating effect Effects 0.000 description 3
- 230000005855 radiation Effects 0.000 description 3
- 238000001959 radiotherapy Methods 0.000 description 3
- 238000003753 real-time PCR Methods 0.000 description 3
- 230000004043 responsiveness Effects 0.000 description 3
- 230000007017 scission Effects 0.000 description 3
- 239000013605 shuttle vector Substances 0.000 description 3
- 238000001356 surgical procedure Methods 0.000 description 3
- 230000008685 targeting Effects 0.000 description 3
- 238000012546 transfer Methods 0.000 description 3
- 230000003612 virological effect Effects 0.000 description 3
- 230000003313 weakening effect Effects 0.000 description 3
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 2
- 102000040650 (ribonucleotides)n+m Human genes 0.000 description 2
- PRDFBSVERLRRMY-UHFFFAOYSA-N 2'-(4-ethoxyphenyl)-5-(4-methylpiperazin-1-yl)-2,5'-bibenzimidazole Chemical compound C1=CC(OCC)=CC=C1C1=NC2=CC=C(C=3NC4=CC(=CC=C4N=3)N3CCN(C)CC3)C=C2N1 PRDFBSVERLRRMY-UHFFFAOYSA-N 0.000 description 2
- 102000004091 Caspase-8 Human genes 0.000 description 2
- 108090000538 Caspase-8 Proteins 0.000 description 2
- 102100026550 Caspase-9 Human genes 0.000 description 2
- 108090000566 Caspase-9 Proteins 0.000 description 2
- 241000702421 Dependoparvovirus Species 0.000 description 2
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 2
- 108010010803 Gelatin Proteins 0.000 description 2
- 101000884271 Homo sapiens Signal transducer CD24 Proteins 0.000 description 2
- 208000026350 Inborn Genetic disease Diseases 0.000 description 2
- 102000013462 Interleukin-12 Human genes 0.000 description 2
- 108010065805 Interleukin-12 Proteins 0.000 description 2
- 102000004388 Interleukin-4 Human genes 0.000 description 2
- 108090000978 Interleukin-4 Proteins 0.000 description 2
- 102000000704 Interleukin-7 Human genes 0.000 description 2
- 108010002586 Interleukin-7 Proteins 0.000 description 2
- 238000007807 Matrigel invasion assay Methods 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- 108010058682 Mitochondrial Proteins Proteins 0.000 description 2
- 102000006404 Mitochondrial Proteins Human genes 0.000 description 2
- 241000699666 Mus <mouse, genus> Species 0.000 description 2
- 241000699670 Mus sp. Species 0.000 description 2
- 206010029113 Neovascularisation Diseases 0.000 description 2
- 102100038081 Signal transducer CD24 Human genes 0.000 description 2
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 2
- 241000700605 Viruses Species 0.000 description 2
- 230000002159 abnormal effect Effects 0.000 description 2
- 238000011394 anticancer treatment Methods 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 210000000481 breast Anatomy 0.000 description 2
- 230000005880 cancer cell killing Effects 0.000 description 2
- 238000004113 cell culture Methods 0.000 description 2
- 230000004709 cell invasion Effects 0.000 description 2
- 230000012292 cell migration Effects 0.000 description 2
- 230000002950 deficient Effects 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 230000007705 epithelial mesenchymal transition Effects 0.000 description 2
- 238000000684 flow cytometry Methods 0.000 description 2
- MHMNJMPURVTYEJ-UHFFFAOYSA-N fluorescein-5-isothiocyanate Chemical compound O1C(=O)C2=CC(N=C=S)=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 MHMNJMPURVTYEJ-UHFFFAOYSA-N 0.000 description 2
- 229920000159 gelatin Polymers 0.000 description 2
- 239000008273 gelatin Substances 0.000 description 2
- 235000019322 gelatine Nutrition 0.000 description 2
- 235000011852 gelatine desserts Nutrition 0.000 description 2
- 208000016361 genetic disease Diseases 0.000 description 2
- 230000012010 growth Effects 0.000 description 2
- 238000002744 homologous recombination Methods 0.000 description 2
- XMBWDFGMSWQBCA-UHFFFAOYSA-N hydrogen iodide Chemical compound I XMBWDFGMSWQBCA-UHFFFAOYSA-N 0.000 description 2
- 238000001114 immunoprecipitation Methods 0.000 description 2
- 230000004957 immunoregulator effect Effects 0.000 description 2
- 239000003112 inhibitor Substances 0.000 description 2
- 229940117681 interleukin-12 Drugs 0.000 description 2
- 229940028885 interleukin-4 Drugs 0.000 description 2
- 229940100994 interleukin-7 Drugs 0.000 description 2
- 239000012528 membrane Substances 0.000 description 2
- 238000010232 migration assay Methods 0.000 description 2
- 210000001700 mitochondrial membrane Anatomy 0.000 description 2
- 230000036457 multidrug resistance Effects 0.000 description 2
- 239000011148 porous material Substances 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 238000012545 processing Methods 0.000 description 2
- 230000010076 replication Effects 0.000 description 2
- 238000000926 separation method Methods 0.000 description 2
- 230000004083 survival effect Effects 0.000 description 2
- 238000002560 therapeutic procedure Methods 0.000 description 2
- 238000002054 transplantation Methods 0.000 description 2
- 102000003390 tumor necrosis factor Human genes 0.000 description 2
- 230000034512 ubiquitination Effects 0.000 description 2
- 238000010798 ubiquitination Methods 0.000 description 2
- TZCPCKNHXULUIY-RGULYWFUSA-N 1,2-distearoyl-sn-glycero-3-phosphoserine Chemical compound CCCCCCCCCCCCCCCCCC(=O)OC[C@H](COP(O)(=O)OC[C@H](N)C(O)=O)OC(=O)CCCCCCCCCCCCCCCCC TZCPCKNHXULUIY-RGULYWFUSA-N 0.000 description 1
- 102100032533 ADP/ATP translocase 1 Human genes 0.000 description 1
- 102100026397 ADP/ATP translocase 3 Human genes 0.000 description 1
- 230000002407 ATP formation Effects 0.000 description 1
- 102000007469 Actins Human genes 0.000 description 1
- 108010085238 Actins Proteins 0.000 description 1
- 108090000672 Annexin A5 Proteins 0.000 description 1
- 102000004121 Annexin A5 Human genes 0.000 description 1
- 208000019901 Anxiety disease Diseases 0.000 description 1
- 208000023275 Autoimmune disease Diseases 0.000 description 1
- 102000055105 BH3 Interacting Domain Death Agonist Human genes 0.000 description 1
- 108700000712 BH3 Interacting Domain Death Agonist Proteins 0.000 description 1
- 208000024172 Cardiovascular disease Diseases 0.000 description 1
- 101710150820 Cellular tumor antigen p53 Proteins 0.000 description 1
- 108091006146 Channels Proteins 0.000 description 1
- 208000035473 Communicable disease Diseases 0.000 description 1
- 102100030497 Cytochrome c Human genes 0.000 description 1
- 108010052832 Cytochromes Proteins 0.000 description 1
- 102000018832 Cytochromes Human genes 0.000 description 1
- 108010075031 Cytochromes c Proteins 0.000 description 1
- 238000012270 DNA recombination Methods 0.000 description 1
- 206010012559 Developmental delay Diseases 0.000 description 1
- 241000588724 Escherichia coli Species 0.000 description 1
- 101000768061 Escherichia phage P1 Antirepressor protein 1 Proteins 0.000 description 1
- 102100024785 Fibroblast growth factor 2 Human genes 0.000 description 1
- 108090000379 Fibroblast growth factor 2 Proteins 0.000 description 1
- GHASVSINZRGABV-UHFFFAOYSA-N Fluorouracil Chemical compound FC1=CNC(=O)NC1=O GHASVSINZRGABV-UHFFFAOYSA-N 0.000 description 1
- 101150112014 Gapdh gene Proteins 0.000 description 1
- 206010064571 Gene mutation Diseases 0.000 description 1
- ZWZWYGMENQVNFU-UHFFFAOYSA-N Glycerophosphorylserin Natural products OC(=O)C(N)COP(O)(=O)OCC(O)CO ZWZWYGMENQVNFU-UHFFFAOYSA-N 0.000 description 1
- 101000796932 Homo sapiens ADP/ATP translocase 1 Proteins 0.000 description 1
- 101000718437 Homo sapiens ADP/ATP translocase 3 Proteins 0.000 description 1
- 101000610605 Homo sapiens Tumor necrosis factor receptor superfamily member 10A Proteins 0.000 description 1
- 101000610604 Homo sapiens Tumor necrosis factor receptor superfamily member 10B Proteins 0.000 description 1
- 102000008070 Interferon-gamma Human genes 0.000 description 1
- 108010074328 Interferon-gamma Proteins 0.000 description 1
- 108010050904 Interferons Proteins 0.000 description 1
- 102000014150 Interferons Human genes 0.000 description 1
- FBOZXECLQNJBKD-ZDUSSCGKSA-N L-methotrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-ZDUSSCGKSA-N 0.000 description 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 description 1
- 102000013013 Member 2 Subfamily G ATP Binding Cassette Transporter Human genes 0.000 description 1
- 108010090306 Member 2 Subfamily G ATP Binding Cassette Transporter Proteins 0.000 description 1
- 206010028116 Mucosal inflammation Diseases 0.000 description 1
- 201000010927 Mucositis Diseases 0.000 description 1
- 108091028043 Nucleic acid sequence Proteins 0.000 description 1
- 101710129178 Outer plastidial membrane protein porin Proteins 0.000 description 1
- 101710179684 Poly [ADP-ribose] polymerase Proteins 0.000 description 1
- 102100023712 Poly [ADP-ribose] polymerase 1 Human genes 0.000 description 1
- 108010029485 Protein Isoforms Proteins 0.000 description 1
- 102000001708 Protein Isoforms Human genes 0.000 description 1
- 108700008625 Reporter Genes Proteins 0.000 description 1
- 102000018066 Subfamily G ATP Binding Cassette Transporter Human genes 0.000 description 1
- 108010091128 Subfamily G ATP Binding Cassette Transporter Proteins 0.000 description 1
- 210000001744 T-lymphocyte Anatomy 0.000 description 1
- 108700012411 TNFSF10 Proteins 0.000 description 1
- 208000024313 Testicular Neoplasms Diseases 0.000 description 1
- 206010057644 Testis cancer Diseases 0.000 description 1
- 102100040113 Tumor necrosis factor receptor superfamily member 10A Human genes 0.000 description 1
- 102100040112 Tumor necrosis factor receptor superfamily member 10B Human genes 0.000 description 1
- 108700005077 Viral Genes Proteins 0.000 description 1
- 102000004962 Voltage-dependent anion channels Human genes 0.000 description 1
- 108090001129 Voltage-dependent anion channels Proteins 0.000 description 1
- 102100037820 Voltage-dependent anion-selective channel protein 1 Human genes 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 230000001464 adherent effect Effects 0.000 description 1
- 208000026935 allergic disease Diseases 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 229940035676 analgesics Drugs 0.000 description 1
- 239000000730 antalgic agent Substances 0.000 description 1
- 230000000340 anti-metabolite Effects 0.000 description 1
- 239000000427 antigen Substances 0.000 description 1
- 108091007433 antigens Proteins 0.000 description 1
- 102000036639 antigens Human genes 0.000 description 1
- 229940100197 antimetabolite Drugs 0.000 description 1
- 239000002256 antimetabolite Substances 0.000 description 1
- 239000003972 antineoplastic antibiotic Substances 0.000 description 1
- 230000005975 antitumor immune response Effects 0.000 description 1
- 230000036506 anxiety Effects 0.000 description 1
- 230000006907 apoptotic process Effects 0.000 description 1
- 230000005540 biological transmission Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 230000008468 bone growth Effects 0.000 description 1
- AIYUHDOJVYHVIT-UHFFFAOYSA-M caesium chloride Inorganic materials [Cl-].[Cs+] AIYUHDOJVYHVIT-UHFFFAOYSA-M 0.000 description 1
- 239000006143 cell culture medium Substances 0.000 description 1
- 230000024245 cell differentiation Effects 0.000 description 1
- 230000010261 cell growth Effects 0.000 description 1
- 239000006285 cell suspension Substances 0.000 description 1
- 230000003833 cell viability Effects 0.000 description 1
- 210000001072 colon Anatomy 0.000 description 1
- 239000002299 complementary DNA Substances 0.000 description 1
- 238000009833 condensation Methods 0.000 description 1
- 230000005494 condensation Effects 0.000 description 1
- 230000001276 controlling effect Effects 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- 238000012258 culturing Methods 0.000 description 1
- 210000004292 cytoskeleton Anatomy 0.000 description 1
- 239000002254 cytotoxic agent Substances 0.000 description 1
- 231100000599 cytotoxic agent Toxicity 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 230000000593 degrading effect Effects 0.000 description 1
- 230000001066 destructive effect Effects 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 238000002651 drug therapy Methods 0.000 description 1
- 230000004064 dysfunction Effects 0.000 description 1
- 230000002124 endocrine Effects 0.000 description 1
- 210000002889 endothelial cell Anatomy 0.000 description 1
- 230000037149 energy metabolism Effects 0.000 description 1
- 230000005284 excitation Effects 0.000 description 1
- 230000029142 excretion Effects 0.000 description 1
- 238000007667 floating Methods 0.000 description 1
- 229960002949 fluorouracil Drugs 0.000 description 1
- 229940044627 gamma-interferon Drugs 0.000 description 1
- 238000007804 gelatin zymography Methods 0.000 description 1
- 238000007429 general method Methods 0.000 description 1
- 230000034659 glycolysis Effects 0.000 description 1
- 208000037824 growth disorder Diseases 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 230000006801 homologous recombination Effects 0.000 description 1
- 230000036737 immune function Effects 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 208000027866 inflammatory disease Diseases 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 229940079322 interferon Drugs 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 239000002502 liposome Substances 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 201000005202 lung cancer Diseases 0.000 description 1
- 208000020816 lung neoplasm Diseases 0.000 description 1
- 238000013507 mapping Methods 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 239000002609 medium Substances 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 230000001394 metastastic effect Effects 0.000 description 1
- 206010061289 metastatic neoplasm Diseases 0.000 description 1
- 229960000485 methotrexate Drugs 0.000 description 1
- 239000011325 microbead Substances 0.000 description 1
- 238000001000 micrograph Methods 0.000 description 1
- 230000002438 mitochondrial effect Effects 0.000 description 1
- 239000002836 nanoconjugate Substances 0.000 description 1
- 239000002773 nucleotide Substances 0.000 description 1
- 125000003729 nucleotide group Chemical group 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 230000005305 organ development Effects 0.000 description 1
- 238000004806 packaging method and process Methods 0.000 description 1
- 230000036961 partial effect Effects 0.000 description 1
- 150000003904 phospholipids Chemical class 0.000 description 1
- HAGVCKULCLQGRF-UHFFFAOYSA-N pifithrin Chemical compound [Br-].C1=CC(C)=CC=C1C(=O)CN1[C+](N)SC2=C1CCCC2 HAGVCKULCLQGRF-UHFFFAOYSA-N 0.000 description 1
- 239000013600 plasmid vector Substances 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 238000004393 prognosis Methods 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 230000004952 protein activity Effects 0.000 description 1
- 230000017854 proteolysis Effects 0.000 description 1
- 108700015048 receptor decoy activity proteins Proteins 0.000 description 1
- 230000006798 recombination Effects 0.000 description 1
- 238000005215 recombination Methods 0.000 description 1
- 238000003571 reporter gene assay Methods 0.000 description 1
- 230000027756 respiratory electron transport chain Effects 0.000 description 1
- 238000010839 reverse transcription Methods 0.000 description 1
- 238000007790 scraping Methods 0.000 description 1
- 239000012679 serum free medium Substances 0.000 description 1
- 230000011664 signaling Effects 0.000 description 1
- 238000009097 single-agent therapy Methods 0.000 description 1
- 210000003491 skin Anatomy 0.000 description 1
- 208000017520 skin disease Diseases 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 230000002194 synthesizing effect Effects 0.000 description 1
- 238000011521 systemic chemotherapy Methods 0.000 description 1
- 201000003120 testicular cancer Diseases 0.000 description 1
- -1 that is Proteins 0.000 description 1
- 230000002103 transcriptional effect Effects 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
- 230000005909 tumor killing Effects 0.000 description 1
- 230000005760 tumorsuppression Effects 0.000 description 1
- 241001430294 unidentified retrovirus Species 0.000 description 1
- 230000006711 vascular endothelial growth factor production Effects 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
- C12N15/1138—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against receptors or cell surface proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/14—Type of nucleic acid interfering N.A.
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/50—Physical structure
- C12N2310/53—Physical structure partially self-complementary or closed
- C12N2310/531—Stem-loop; Hairpin
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Medicinal Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Biomedical Technology (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- General Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Microbiology (AREA)
- Plant Pathology (AREA)
- Biophysics (AREA)
- Physics & Mathematics (AREA)
- Oncology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| KR1020110014820A KR20120095263A (ko) | 2011-02-18 | 2011-02-18 | Ａｄｅｎｉｎｅ ｎｕｃｌｅｏｔｉｄｅ ｔｒａｎｓｌｏｃａｔｏｒ ２ ｍＲＮＡ 발현을 감소시켜 유방암을 치료하는 방법 |
| KR10-2011-0014820 | 2011-02-18 | ||
| PCT/KR2011/007849 WO2012111900A1 (en) | 2011-02-18 | 2011-10-20 | Method for treating breast cancer by decreasing the expression of adenine nucleotide translocator 2 mrna |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| JP2014506888A true JP2014506888A (ja) | 2014-03-20 |
Family
ID=46672787
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2013554383A Pending JP2014506888A (ja) | 2011-02-18 | 2011-10-20 | アデニンヌクレオチドトランスケータ２ｍＲＮＡ発現を減少させて乳房癌を治療する方法 |
Country Status (5)
| Country | Link |
|---|---|
| EP (1) | EP2675468A4 (zh) |
| JP (1) | JP2014506888A (zh) |
| KR (1) | KR20120095263A (zh) |
| CN (1) | CN103379914B (zh) |
| WO (1) | WO2012111900A1 (zh) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103263676A (zh) * | 2013-02-07 | 2013-08-28 | 魏敏杰 | 一种应用miR-487a逆转乳腺癌耐药的方法 |
| KR101681597B1 (ko) * | 2014-01-17 | 2016-12-01 | 주식회사 바이오인프라 | ANT2 siRNA를 함유하는 HER2 표적 항암제에 대한 내성 극복을 위한 조성물 |
| KR102211972B1 (ko) * | 2018-08-02 | 2021-02-04 | 엑소젠 피티이. 엘티디 | 액체생검 다중 암 유전자 바이오마커를 이용한 유방암 조기진단 및 치료 후 모니터링 방법 |
| CN112516317B (zh) * | 2020-12-10 | 2021-12-17 | 暨南大学附属第一医院（广州华侨医院） | 一种预防和治疗癌症的药物组合物及其应用 |
| KR102604882B1 (ko) | 2021-07-01 | 2023-11-21 | 인천대학교 산학협력단 | 신규 특이적 항암 및 항염증 siRNA 및 이의 용도 |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20090202623A1 (en) * | 2006-04-11 | 2009-08-13 | Chul Woo Kim | Gene therapy for cancer using small interfering rna specific to ant2 and a method to overcome tolerance to antitumor agent |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1599196A4 (en) * | 2003-01-17 | 2006-05-31 | Threshold Pharmaceuticals Inc | ANTICANCER THERAPY |
| FR2850105B1 (fr) * | 2003-01-21 | 2006-07-28 | Theraptosis | Moyens pour la regulation de l'expression des isoformes humaines de l'ant |
| US8399426B2 (en) * | 2006-04-11 | 2013-03-19 | Bioinfra Inc. | Method for treating breast cancer using adenine nucleotide translocator 2 (ANT2) siRNA or ANT2 shRNA |
| WO2008026946A2 (en) * | 2006-08-30 | 2008-03-06 | Genesis Research And Development Corporation Limited | Compositions and methods for the treatment and prevention of neoplastic disorders |
| WO2009126335A2 (en) * | 2008-04-08 | 2009-10-15 | University Of Florida Research Foundation, Inc. | Ant2 inhibitor compounds and methods of use thereof |
-
2011
- 2011-02-18 KR KR1020110014820A patent/KR20120095263A/ko active Search and Examination
- 2011-10-20 EP EP11858532.2A patent/EP2675468A4/en not_active Withdrawn
- 2011-10-20 JP JP2013554383A patent/JP2014506888A/ja active Pending
- 2011-10-20 WO PCT/KR2011/007849 patent/WO2012111900A1/en active Application Filing
- 2011-10-20 CN CN201180067534.0A patent/CN103379914B/zh active Active
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20090202623A1 (en) * | 2006-04-11 | 2009-08-13 | Chul Woo Kim | Gene therapy for cancer using small interfering rna specific to ant2 and a method to overcome tolerance to antitumor agent |
Non-Patent Citations (3)
| Title |
|---|
| JPN6014035443; ＢＭＣ Ｃａｎｃｅｒ １０：３９１, 2010, ｐｐ．１-９ * |
| JPN6014035445; Ｂｒｅａｓｔ Ｃａｎｃｅｒ Ｒｅｓｅａｒｃｈ １０：Ｒ１１, 2008, ｐｐ．１-１４ * |
| JPN6014035446; Ｍｏｌｅｃｕｌａｒ Ｃａｎｃｅｒ ９：２６２, 2010, ｐｐ．１-１２ * |
Also Published As
| Publication number | Publication date |
|---|---|
| WO2012111900A1 (en) | 2012-08-23 |
| EP2675468A4 (en) | 2014-10-22 |
| KR20120095263A (ko) | 2012-08-28 |
| EP2675468A1 (en) | 2013-12-25 |
| CN103379914B (zh) | 2016-02-17 |
| CN103379914A (zh) | 2013-10-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US10351851B2 (en) | Methods and compositions for enhancing the therapeutic effect of anti-tumor T cells | |
| Yang et al. | MiR-146b-5p overexpression attenuates stemness and radioresistance of glioma stem cells by targeting HuR/lincRNA-p21/β-catenin pathway | |
| Liu et al. | Microvesicle-delivery miR-150 promotes tumorigenesis by up-regulating VEGF, and the neutralization of miR-150 attenuate tumor development | |
| US12060619B2 (en) | Treatment of angiogenesis disorders | |
| Murmann et al. | Induction of DISE in ovarian cancer cells in vivo | |
| JP2007530029A (ja) | アネキシンｉｉ及びその使用 | |
| Tang et al. | Downregulation of CXCR7 inhibits proliferative capacity and stem cell-like properties in breast cancer stem cells | |
| JP2014506888A (ja) | アデニンヌクレオチドトランスケータ２ｍＲＮＡ発現を減少させて乳房癌を治療する方法 | |
| KR102067402B1 (ko) | 조절자 Ｔ 세포에 특이적으로 존재하는 새로운 표면단백질 Ｌｒｉｇ-1의 용도 | |
| CN114174495A (zh) | 肿瘤浸润淋巴细胞疗法及其用途 | |
| Uemae et al. | CXCL12 secreted from glioma stem cells regulates their proliferation | |
| Gao et al. | MiR-30c facilitates natural killer cell cytotoxicity to lung cancer through targeting GALNT7 | |
| EP2816107B1 (en) | Method of expanding hematopoietic stem cells | |
| US8399426B2 (en) | Method for treating breast cancer using adenine nucleotide translocator 2 (ANT2) siRNA or ANT2 shRNA | |
| KR102094747B1 (ko) | 조절자 Ｔ 세포에 특이적으로 존재하는 새로운 표면단백질 Ｌｒｉｇ-1의 용도 | |
| Wang et al. | Suppression of growth of pancreatic cancer cell and expression of vascular endothelial growth factor by gene silencing with RNA interference | |
| JP2010536380A (ja) | 転写後遺伝子サイレンシングのための方法及び組成物 | |
| CA2567526A1 (en) | Cancer treatment method by inhibiting mage gene expression or function | |
| KR102317415B1 (ko) | 조절자 Ｔ 세포에 특이적으로 존재하는 새로운 표면단백질 Ｌｒｉｇ-1의 용도 | |
| JPWO2005063984A1 (ja) | 遺伝子発現を抑制する二本鎖ｒｎａ | |
| US20150315276A1 (en) | Inhibitor of integrin for the treatment or prevention of tumours |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20130814 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20140826 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20141125 |
|
| A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20150602 |